Every Form 4 that Alkermes Inc. plc (ALKS) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow ALKS and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ALKS filings page.
Alkermes plc. reports that David Joseph Gaffin, EVP, CLO of Alkermes, Inc., sold 2,034 ordinary shares on October 2, 2026, at $41.03 per share. The sale was effected pursuant to a Rule 10b5-1 trading plan adopted November 19, 2025. Following the sale, Gaffin directly held 221,388 ordinary shares.
Alkermes plc. (ALKS) reported that executive vice president and chief legal officer David Joseph Gaffin sold 2,034 Ordinary Shares on September 3, 2026 at $48.01 per share in a market transaction. After this sale, he holds 223,422 Ordinary Shares directly, and the transaction was made under a Rule 10b5-1 trading plan adopted on November 19, 2025.
Alkermes plc (ALKS) reported insider activity by Craig C. Hopkinson, EVP R&D and Chief Medical Officer. On 2026-09-01, he exercised 5,000 Employee Stock Options at an exercise price of $24.59 per share to acquire 5,000 Ordinary Shares, and sold 9,000 Ordinary Shares at a weighted average price of $46.986 per share. The option exercise and sale were effected pursuant to a Rule 10b5-1 trading plan adopted on 2025-03-14. After the option exercise, he held 61,276 stock options of this grant, which are fully vested in accordance with their terms.
Alkermes plc. SVP and Chief Commercial Officer Christian Todd Nichols reported open-market sales of Alkermes ordinary shares. On 2026-08-17, he sold 6,912 shares at a weighted average price of $49.1851 and 664 shares at a weighted average price of $49.6526, in transactions made under a Rule 10b5-1 trading plan. Each sale was executed through multiple trades within disclosed price ranges.
Alkermes plc reported that President & CEO Jackson Blair Curtis received two grants of Employee Stock Options on 2026-08-05. One award covers 93,229 options with an exercise price of $49.6100 per share, vesting in four equal annual installments commencing on 8/5/2027 and expiring on 2036-08-05. A second award covers 124,305 options at the same exercise price and expiration, vesting in two tranches only if Alkermes’s ordinary share trades at certain pre-specified price levels for 30 consecutive trading days and after two years of continuous service as CEO, or less in the event of a change in control.
Nancy Lynn Snyderman, a director of Alkermes plc, exercised fully vested non-qualified stock options to acquire 44,472 Ordinary Shares at an exercise price of $46.72 per share on August 3, 2026. She then sold 44,472 shares at a weighted average price of $50.3480 per share, in transactions priced between $50.07 and $50.70. Following these transactions, 20,783 Ordinary Shares are held indirectly through the Nancy Lynn Snyderman Revocable Trust.
Alkermes plc. executive Craig C. Hopkinson, EVP R&D and Chief Medical Officer, exercised employee stock options for a total of 5,000 ordinary shares at exercise prices of $19.34 and $24.59, and on 2026-08-03 sold 9,000 ordinary shares at $48.58 per share. These option exercises and the share sale were effected pursuant to a Rule 10b5-1 trading plan adopted on 3/14/2025, and the exercised options were fully vested.
On 2026-08-03, Alkermes plc executive David Joseph Gaffin, EVP and CLO, sold 2,034 Ordinary Shares of Alkermes at an average price of $48.58 per share. The sale, reported as a sale in the open market or a private transaction, was executed under a Rule 10b5-1 trading plan adopted on 11/19/2025, and he now directly holds 225,456 Ordinary Shares.
Alkermes plc. executive David Joseph Gaffin, EVP and Chief Legal Officer of Alkermes, Inc., reported an open-market sale of 2,034 Ordinary Shares on July 6, 2026 at $54.03 per share. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan adopted on November 19, 2025. Following this sale, he directly holds 227,490 Ordinary Shares, so the transaction represents only a small fraction of his overall position.
Alkermes plc executive Craig C. Hopkinson, EVP R&D and Chief Medical Officer, reported a combination of option exercise and share sales in Ordinary Shares. He exercised employee stock options for 5,000 shares at a conversion price of $19.34 per share and, on the same date, sold a total of 9,000 Ordinary Shares in open-market transactions at weighted average prices of $51.4613 and $52.1314. The filing notes these transactions were executed under a Rule 10b5-1 trading plan adopted on March 14, 2025. Following the transactions, he directly holds 73,389 Ordinary Shares and 1,356 employee stock options.
Alkermes plc director Christopher I. Wright reported an open-market sale of 2,000 Ordinary Shares at a price of $45.10 per share. After this transaction, he directly holds 25,680 Ordinary Shares.
The sale was executed under a pre-arranged Rule 10b5-1 trading plan adopted by Wright on March 11, 2026, indicating the trade was scheduled in advance rather than timed discretionarily.
Alkermes plc EVP and Chief Legal Officer David Joseph Gaffin reported an open-market sale of 2,034 Ordinary Shares of Alkermes on June 4, 2026 at an average price of $43.05 per share. After this transaction, he directly holds 229,524 Ordinary Shares. The sale was carried out under a pre-arranged Rule 10b5-1 trading plan that he adopted on November 19, 2025, indicating it was scheduled in advance rather than timed opportunistically.
Alkermes plc executive Craig C. Hopkinson, EVP R&D and Chief Medical Officer, reported an exercise-and-sale transaction in company stock. He exercised stock options to acquire 5,000 Ordinary Shares at $19.34 per share and sold 9,000 Ordinary Shares in an open-market transaction at a weighted average price of $41.6715 per share.
Both the option exercise and the share sale were carried out under a Rule 10b5-1 trading plan adopted on March 14, 2025, meaning they were pre-arranged. The sale price reflects multiple trades between $41.37 and $42.19. After these transactions, Hopkinson directly holds 77,389 Ordinary Shares.
Alkermes plc VP of Finance (Interim PAO) Samuel Joseph Parisi reported an exercise-and-sell transaction in company stock. On May 29, 2026, he exercised employee stock options to acquire a total of 16,217 Ordinary Shares at exercise prices of $19.34 and $20.03 per share. He then sold 16,217 Ordinary Shares in open-market transactions at a weighted average price of $42.3634 per share, with individual sale prices ranging from $42.245 to $42.50. After these transactions, he directly held 7,717 Ordinary Shares of Alkermes.
Alkermes plc director Christopher I. Wright reported several compensation-related equity transactions. On May 21, 2026, 6,142 restricted stock units were exercised into ordinary shares, with 1,475 shares withheld at $36.95 per share to cover tax obligations rather than sold on the market. Wright also received new awards on May 20, 2026: 5,409 restricted stock units and 11,538 non-qualified stock options with a $36.98 exercise price, expiring on May 20, 2036. Following these transactions, he holds 27,680 ordinary shares directly. Footnotes clarify each restricted stock unit converts into one ordinary share and that the new awards vest in full around the next annual general meeting.
Alkermes plc. director Wilson Frank Anders reported several routine equity compensation moves. On May 21, 2026, he exercised 6,142 Restricted Stock Units, receiving the same number of ordinary shares, and had 1,475 ordinary shares withheld to cover tax obligations at $36.95 per share. Following these transactions, he directly held 35,751 ordinary shares.
On May 20, 2026, he received a new grant of 5,409 Restricted Stock Units, each representing a contingent right to one ordinary share, and a Non Qualified Stock Option for 11,538 ordinary shares with an exercise price of $36.98 per share, expiring on May 20, 2036. The filing describes these events as grants, vesting, and tax-withholding rather than open-market buying or selling.
Alkermes plc. director Nancy Lynn Snyderman, MD reported routine equity compensation activity and related tax withholding. On May 21, 2026, she exercised a previously granted restricted stock unit award for 6,142 ordinary shares, and 1,475 shares were disposed of to cover tax obligations, not as an open-market sale.
On May 20, 2026, she received new equity awards: 5,409 restricted stock units, each representing the right to one ordinary share, and a non qualified stock option for 11,538 ordinary shares with a $36.98 exercise price expiring in 2036. A separate entry shows 20,783 ordinary shares held indirectly through the Nancy Lynn Snyderman Revocable Trust, where she is sole trustee and sole beneficiary.
Alkermes plc director Brian P. McKeon reported multiple equity transactions involving ordinary shares and equity awards. He exercised restricted stock units covering 6,142 ordinary shares, with 1,475 shares withheld at $36.95 per share to satisfy tax obligations, leaving 38,536 ordinary shares held directly after the tax-withholding disposition.
He also received a new restricted stock unit award for 5,409 units and a non-qualified stock option for 11,538 shares with a $36.98 exercise price, both granted at no cash cost and each RSU representing a contingent right to one ordinary share. In addition, 10,000 ordinary shares are held indirectly by The Brian P. McKeon Revocable Trust, of which he and his wife are trustees.
Alkermes plc director Nancy Lurker reported routine equity compensation and related share activity. On May 20, 2026, she received a grant of 5,409 Restricted Stock Units and a Non Qualified Stock Option for 11,538 ordinary shares with an exercise price of $36.98 per share, expiring on May 20, 2036.
On May 21, 2026, 6,142 Restricted Stock Units were exercised into ordinary shares, and 1,475 shares were disposed of at $36.95 per share to satisfy tax obligations. Following these transactions, she directly held 18,222 ordinary shares.
Alkermes plc. director Cato T. Laurencin reported routine equity compensation activity. He received 5,409 restricted stock units and 11,538 non-qualified stock options with a $36.98 exercise price. On the next day, 6,142 RSUs were exercised into ordinary shares and 1,475 shares were withheld to cover tax obligations, leaving him with 33,769 ordinary shares directly held.
Alkermes plc director Richard Gaynor reported an amended insider filing reflecting equity awards granted as compensation. He received a restricted stock unit award for 5,409 units, each representing a contingent right to receive one ordinary share.
He was also granted a non-qualified stock option for 11,538 ordinary shares with an exercise price of $36.98 per share, expiring on May 20, 2036. All shares subject to these awards vest, and for the option become exercisable, in full on the earlier of the one-year anniversary of the grant date or the issuer’s next annual general meeting of shareholders that occurs at least 50 weeks after the grant date. The amendment corrects previously misreported vesting terms.
Alkermes plc director Shane Cooke reported equity awards and corrected vesting terms for a prior grant. He received a restricted stock unit award covering 5,409 ordinary shares and a non-qualified stock option for 11,538 ordinary shares at an exercise price of $36.98 per share, expiring on May 20, 2036. The filing explains that both awards vest in full on the earlier of the one-year anniversary of the grant date or the next annual general meeting of shareholders that occurs at least 50 weeks after the grant date. An amendment clarifies that earlier vesting terms were reported incorrectly and confirms the correct schedule.
Alkermes plc. director Richard Gaynor reported routine equity compensation and related share movements. He exercised 6,142 restricted stock units into ordinary shares and had 1,475 shares withheld to cover tax obligations at $36.95 per share, leaving 35,751 ordinary shares directly held after the withholding.
Gaynor also received new awards on ordinary shares: 5,409 restricted stock units and 11,538 non-qualified stock options with a $36.98 exercise price. Both the new RSUs and options vest fully on May 20, 2027, and the option award is exercisable after vesting through May 20, 2036.
Alkermes plc director Shane Cooke reported routine equity compensation activity and related tax withholding. He exercised 6,142 restricted stock units into ordinary shares and had 3,207 shares withheld to cover tax obligations at a price of $36.95 per share, which is not an open-market sale.
Cooke also received new awards on May 20, 2026, including 5,409 restricted stock units and a non-qualified stock option for 11,538 ordinary shares with an exercise price of $36.98 per share, both vesting in full on May 20, 2027. Following these transactions, he holds 109,886 ordinary shares directly.
Alkermes plc executive David Joseph Gaffin, EVP and Chief Legal Officer of Alkermes, Inc., reported an open-market sale of 2,034 Ordinary Shares at $33.20 per share. The transaction was made under a pre-arranged Rule 10b5-1 trading plan adopted by the reporting person. Following this sale, he continues to hold 231,558 Ordinary Shares directly, indicating a substantially larger remaining equity position in the company.
Alkermes plc EVP R&D and Chief Medical Officer Craig C. Hopkinson exercised employee stock options for 5,000 ordinary shares at $19.34 per share and then sold 9,000 ordinary shares at a weighted average price of $33.3955 on May 1, 2026.
Both the option exercise and the open-market sale were carried out under a pre-arranged Rule 10b5-1 trading plan adopted on March 14, 2025. After these transactions, Hopkinson directly held 81,389 ordinary shares, and the exercised options are fully vested in accordance with their terms.
Alkermes plc. director Nancy Lurker reported a routine equity compensation event. She exercised a restricted stock unit award covering 3,751 ordinary shares, converting it into the same number of ordinary shares at a stated price of $0.00 per share.
Of these shares, 901 ordinary shares were withheld at $33.36 per share to cover tax obligations related to the vesting, leaving her with 13,555 ordinary shares held directly after the transactions. The restricted stock units vest in three equal annual installments beginning on April 11, 2025.
Alkermes plc. executive David Joseph Gaffin, EVP and Chief Legal Officer of Alkermes, Inc., reported an open-market sale of company ordinary shares. He sold 2,034 Ordinary Shares at an average price of $34.57 per share. After this transaction, he directly holds 233,592 Ordinary Shares, indicating the sale was a small portion of his overall position. The transaction was carried out under a pre-arranged Rule 10b5-1 trading plan adopted by the reporting person.
Alkermes plc EVP R&D and Chief Medical Officer Craig C. Hopkinson exercised employee stock options for 5,000 Ordinary Shares at an exercise price of $19.34 per share and acquired the related shares. On the same date, he sold 9,000 Ordinary Shares at a weighted average price of $35.5116 per share in an open-market transaction.
Both the option exercise and the share sale were effected under a pre-arranged Rule 10b5-1 trading plan adopted on March 14, 2025. After these transactions, Hopkinson directly held 85,389 Ordinary Shares. The options exercised were fully vested in accordance with their terms, and no remaining derivative positions are shown in this filing.
Reed Joshua reported acquisition or exercise transactions in this Form 4 filing.
Alkermes plc reported that its Senior Vice President and Chief Financial Officer, Joshua Reed, received new equity awards. On March 2, 2026, he was granted 66,430 employee stock options and 30,854 restricted stock units, each RSU representing one ordinary share.
The stock options and RSUs vest in four equal annual installments starting on March 2, 2027, meaning the awards will fully vest over four years if service-based conditions are met. These are non-cash compensation grants and do not represent open-market purchases or sales of Alkermes shares.
POPS RICHARD F reported acquisition or exercise transactions in this Form 4 filing.
Alkermes plc reported that Director and CEO Richard F. Pops received a grant of 88,843 restricted stock units on March 2, 2026. Each unit represents a contingent right to receive one ordinary share. The entire award is scheduled to vest on December 31, 2026 in connection with the company’s previously announced leadership transition.
Alkermes plc VP, Finance (Interim PAO) Samuel Joseph Parisi reported equity awards and a planned share sale. On 3/2/2026, he received an employee stock option for 15,033 shares at an exercise price of $0.00, vesting in four equal annual installments starting 3/2/2027.
He also received a restricted stock unit award for 14,176 units, each representing one ordinary share, vesting in four equal annual installments beginning 3/2/2027. On the same date, he sold 6,890 ordinary shares at $29.29 per share in an open-market transaction under a pre-established Rule 10b5-1 trading plan adopted on 11/7/2025.
Alkermes plc senior vice president and chief commercial officer Christian Todd Nichols reported both equity awards and a share sale. He received an employee stock option for 66,430 shares and a restricted stock unit award for 30,854 units, each at a grant price of $0.00 per share. Both the option and RSUs vest in four equal annual installments, starting on 3/2/2027. On the same date, he sold 6,000 ordinary shares at $30.00 per share in an open-market transaction effected under a pre-established Rule 10b5-1 trading plan adopted on 11/19/2025, and held 109,769 ordinary shares afterward.
Alkermes plc reported that Executive Vice President and Chief Operating Officer Jackson Blair Curtis received new equity awards. He was granted stock options for 94,900 shares at an exercise price of $0.00 per share and a restricted stock unit award covering 44,078 shares, both held directly.
The stock options vest and become exercisable in four equal annual installments starting on March 2, 2027. The restricted stock units each represent the right to receive one ordinary share and also vest in four equal annual installments beginning on March 2, 2027, tying a significant portion of his compensation to long-term company performance.
Alkermes plc EVP R&D and Chief Medical Officer Craig C. Hopkinson reported a mix of equity awards, option exercises, and a share sale. He exercised employee stock options for 5,000 ordinary shares at an exercise price of $19.34 per share, then sold 9,000 ordinary shares at a weighted average price of $29.7206 per share in open-market transactions under a Rule 10b5-1 trading plan adopted on 3/14/2025. He also received a new grant of 83,037 employee stock options and a 38,568-share restricted stock unit award, both vesting in four equal annual installments starting 3/2/2027. After these transactions, he directly holds 89,389 ordinary shares of Alkermes.
Alkermes plc executive David Joseph Gaffin, EVP and CLO of Alkermes, Inc., reported a mix of share sales and new equity awards. He sold a total of 4,068 ordinary shares in open-market transactions at $29.29 and $29.76 per share under a pre-arranged Rule 10b5-1 trading plan and held 235,626 shares after the latest sale. He also received a grant of 78,292 stock options and 36,364 restricted stock units, which vest in four equal annual installments starting on March 2, 2027.
Alkermes plc vice president of finance Samuel Joseph Parisi reported equity transactions involving restricted stock units and ordinary shares. On February 26, 2026, he acquired 2,747 ordinary shares through the exercise/conversion of a restricted stock unit award, with each unit representing one ordinary share. Following this, a separate transaction disposed of 808 ordinary shares at $30.73 per share to cover tax obligations, leaving him with 14,607 ordinary shares held directly. The underlying restricted stock unit award vests in four equal annual installments beginning on February 26, 2025.
Alkermes plc SVP and Chief Commercial Officer Christian Todd Nichols reported equity award activity involving restricted stock units and ordinary shares. On 2026-02-26, he exercised 5,410 restricted stock units, which converted into 5,410 ordinary shares at a stated price of $0.0000 per share.
A related Form 4 line shows 2,403 ordinary shares disposed of at $30.73 per share in a code F transaction, which reflects shares withheld to satisfy tax obligations rather than an open-market sale. After these transactions, Nichols directly owned 115,769 ordinary shares and held 10,819 restricted stock units, each representing a contingent right to receive one ordinary share. The restricted stock unit award vests in four equal annual installments beginning on 02/26/2025.
Alkermes plc EVP and COO Jackson Blair Curtis reported equity compensation-related transactions. On February 26, 2026, he acquired 8,322 ordinary shares upon the exercise of a restricted stock unit award, with each unit representing one ordinary share. On the same date, 3,695 ordinary shares were disposed of at $30.73 per share to satisfy tax withholding obligations. Following these transactions, Curtis directly owned 241,308 ordinary shares. The underlying restricted stock units vest in four equal annual installments beginning on February 26, 2025.
Alkermes plc executive Craig C. Hopkinson reported equity award activity involving restricted stock units and ordinary shares. On 2/26/2026, he exercised 6,866 restricted stock units, which converted into 6,866 ordinary shares at a stated price of $0.0000 per share. In a related tax-withholding transaction, 3,049 ordinary shares were disposed of at $30.73 per share to cover tax obligations rather than as an open-market sale. Following these transactions, he directly held 93,389 ordinary shares and 13,732 restricted stock units. Each restricted stock unit represents a contingent right to receive one ordinary share and the award vests in four equal annual installments commencing on 02/26/2025.
Alkermes plc executive David Joseph Gaffin reported equity award activity. On 2/26/2026, he acquired 6,866 restricted stock units and 6,866 ordinary shares through an exercise or conversion of derivative securities. A separate transaction disposed of 3,049 ordinary shares at $30.73 per share to satisfy tax obligations.
After these transactions, Gaffin directly held 13,732 restricted stock units and 239,694 ordinary shares. Each restricted stock unit represents a contingent right to receive one ordinary share, and the award vests in four equal annual installments beginning on 2/26/2025.
Alkermes plc VP Samuel Joseph Parisi reported equity award activity. On 2/23/2026, 2,283 restricted stock units were exercised or converted into 2,283 ordinary shares at a price of $0.00 per share. A separate transaction disposed of 672 ordinary shares at $32.19 per share to cover tax withholding obligations. Each restricted stock unit represents a contingent right to receive one ordinary share, and the award vests in four equal annual installments starting on 2/23/2024. After these transactions, he directly held 2,284 restricted stock units and 12,668 ordinary shares.
Alkermes plc senior vice president and chief commercial officer Christian Todd Nichols reported equity compensation activity involving restricted stock units and ordinary shares. On 2/23/2026, 6,407 restricted stock units were exercised into 6,407 ordinary shares at a price of $0.00 per share, reflecting a derivative exercise or conversion. To cover tax obligations, 2,845 ordinary shares were disposed of at $32.19 per share through a tax-withholding transaction. After these movements, Nichols directly owned 112,762 ordinary shares. Each restricted stock unit represents a right to receive one ordinary share, and units vest in four equal annual installments beginning 2/23/2024.
Alkermes plc EVP and COO Jackson Blair Curtis reported equity transactions on 2/23/2026. He exercised a restricted stock unit award, converting 8,738 restricted stock units into 8,738 ordinary shares at a stated price of $0.0000 per share.
To cover tax obligations related to this equity compensation, 3,880 ordinary shares were disposed of in a tax-withholding transaction at $32.1900 per share. After these transactions, Curtis directly owned 236,681 ordinary shares. Each restricted stock unit represents one ordinary share and vests in four equal annual installments beginning on 2/23/2024.
Alkermes plc executive Craig C. Hopkinson, EVP R&D and Chief Medical Officer, exercised 7,689 restricted stock units into ordinary shares on February 23, 2026, with each unit converting into one share. On the same date, 3,414 ordinary shares at $32.19 per share were withheld to cover tax obligations, leaving him with 89,572 ordinary shares held directly. The restricted stock unit award vests in four equal annual installments beginning on February 23, 2024.
Alkermes plc executive David Joseph Gaffin, EVP and CLO of Alkermes, Inc., reported the vesting and exercise of 7,689 restricted stock units into ordinary shares on February 23, 2026. In a related tax-withholding disposition, 3,414 ordinary shares were used at $32.19 per share. Following these transactions, he directly holds 235,877 ordinary shares. The restricted stock unit award vests in four equal annual installments beginning February 23, 2024.
Alkermes plc VP, Finance (Interim PAO) Samuel Joseph Parisi reported equity award transactions involving restricted stock units (RSUs) and ordinary shares. On February 18 and 19, 2026, RSU awards were exercised, converting 2,034 and 2,991 RSUs into the same number of ordinary shares at a price of $0.00 per share.
To cover tax obligations, Parisi disposed of 706 ordinary shares at $32.02 and 979 ordinary shares at $32.00 through share withholding transactions coded "F," which are described as payments of tax liability by delivering securities. After these transactions, he directly held 11,057 ordinary shares. Footnotes state that each RSU represents a right to one ordinary share, that one award is fully vested, and another vests in four equal annual installments starting on February 19, 2026.
Alkermes plc SVP and Chief Commercial Officer Christian Todd Nichols reported equity award activity involving restricted stock units (RSUs) and ordinary shares. On February 18 and 19, 2026, RSU awards covering 6,355 and 6,045 units were exercised, with each unit converting into one ordinary share at a price of $0.00 per share.
Following these conversions, Nichols’ direct holdings in ordinary shares increased, with post-transaction balances of 107,301 and 111,477 shares reported. On both dates, the company also withheld 1,869 and 2,277 ordinary shares, respectively, at around $32 per share to cover tax obligations, reducing the final reported balance to 109,200 and then 105,432 shares. Footnotes state that one award is fully vested and another vests in four equal annual installments starting on February 19, 2026.
Alkermes plc executive Jackson Blair Curtis, EVP and Chief Operating Officer, exercised restricted stock units into ordinary shares and delivered shares to cover taxes. On February 18–19, 2026, he converted a total of 18,197 RSUs into ordinary shares.
To satisfy tax withholding, 7,926 ordinary shares were disposed of at prices around $32 per share, described as payment of tax liability rather than open‑market sales. After these transactions, he held 231,823 ordinary shares directly. One RSU award is fully vested, and another vests in four equal annual installments starting February 19, 2026.
Alkermes plc EVP R&D and Chief Medical Officer Craig C. Hopkinson reported equity compensation-related share movements, primarily from restricted stock units (RSUs) converting into ordinary shares. On February 18 and 19, 2026, RSU awards for 8,897 and 7,673 units were exercised, each unit representing one ordinary share.
To cover tax obligations associated with these vestings, 3,504 and 3,407 ordinary shares were automatically withheld and disposed of at prices of $32.02 and $32.00 per share, respectively, characterized as payment of tax liability rather than open-market sales. Following these transactions, Hopkinson directly owned 81,031 Alkermes ordinary shares. One referenced RSU award is noted as fully vested, while another vests in four equal annual installments starting on February 19, 2026.